http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
NecroX-5 prevents hypoxia/reoxygenation injury by inhibiting the mitochondrial calcium uniporter.
Thu, Vu Thi,Kim, Hyoung-Kyu,Long, Le Thanh,Lee, Sung-Ryul,Hanh, Tran My,Ko, Tae Hee,Heo, Hye-Jin,Kim, Nari,Kim, Soon Ha,Ko, Kyung Soo,Rhee, Byoung Doo,Han, Jin British Medical Association 2012 Cardiovascular research Vol.94 No.2
<P>Preservation of mitochondrial function is essential to limit myocardial damage in ischaemic heart disease. We examined the protective effects and mechanism of a new compound, NecroX-5, on rat heart mitochondria in a hypoxia/reoxygenation (HR) model.</P>
( Hye Soo Kim ),( Seung Up Kim ),( Beom Kyung Kim ),( Jun Yong Park ),( Do Young Kim ),( Sang Hoon Ahn ),( Ki Jun Song ),( Ja Yoon Heo ),( My Young Jeon ),( Ji Hye Park ),( Kwang-hyub Han ) 대한간학회 2016 춘·추계 학술대회 (KASL) Vol.2016 No.1
Aims: It is not well known whether the risk of hepatocellular carcinoma (HCC) development in patients with chronic hepatitis B (CHB) treated with oral antiviral agents is similar to that of patients in inactive stage CHB. We compared the risk of HCC development between patients with CHB receiving oral antiviral therapy and those in inactive stage CHB, after adjusting for fibrotic burden. Methods: A total of 1708 patients with CHB who achieved virological response (VR, defined as HBV-DNA <2000 IU/mL) through oral antiviral therapy (NUC-VR group) and 840 inactive carriers who had negative hepatitis B e antigen (HBeAg), normal alanine aminotransferase (ALT) level, and HBV-DNA<2000 IU/mL (IC group) were enrolled. Cumulative rate of HCC development was assessed by Kaplan-meier method with a comparison by log-rank test. Cox regression analysis was performed for multivariate analysis. Rescue therapy was performed, if appropriate. Results: NUC-VR group had a higher portion of male (65.3% vs. 57.5%), higher total billirubin level (median 0.8 mg/dL vs. 0.7 mg/dL), lower serum albumin levels (median 4.4 g/dL vs. 4.6 g/dL), lower platelet count (median 161x103/mm3 vs. 200x103/mm3), higher proportion of ultrasonographic cirrhosis (43.8% vs. 6.3%), and higher LS value (median 7.7 kPa vs. 5.0 kPa) (all p<0.001). On multivariate analysis, NUC-VR group was at a higher risk of HCC development compared with IC group (p<0.001). Conclusions: Even patients who achieved NUC-VR through oral antiviral therapy was at a higher risk of HCC development compared with IC group.